NEWTOWN, PA, November 3, 2014 – Helius Medical Technologies, Inc. (CSE: HSM) (“HMT”, “Helius”, or the “Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, is pleased to announce today the appointment of leading experts to its newly formed Scientific and Medical Advisory Board (“SAB”). The SAB will guide the Company in a range of activities including future clinical trial design, analyzing the science behind the company’s Portable Neuromodulation Stimulator (“PoNS™”) device and identifying other clinical applications for PoNS™ beyond the current research in traumatic brain injury (TBI) and Multiple Sclerosis (MS).
“We are thrilled with such an impressive list of advisors to our Scientific Advisory Board,” said Philippe Deschamps, CEO of Helius. “This is a period of rapid growth and expansion of clinical activity for Helius and access to some of the brightest scientific and medical minds in the industry will ensure the best and broadest path forward.
The inaugural members of the Helius’ scientific advisory board include:
Jonathan Sackier, MB, ChB, FRCS, Scientific Advisory Board chair, surgeon and leader in laparoscopic surgery.
Ron Alterman, M.D., M.B.A., Harvard professor and Chief of Neurosurgery at Beth Israel Deaconess Medical Center, Boston, MA with expertise in movement disorder surgery.
Carl Hauser, M.D., Director of Trauma and attending surgeon at Beth Israel Deaconess Hospital; visiting professor of Surgery at Harvard Medical School.
Scott Parazynski, M.D., Former NASA astronaut, inventor and leader in the medical device and medical research fields.
Gale Pollock, CRNA, FACHE, FAAN, Former Commander of the US Army Medical Command and the Acting Surgeon General of the Army. Fellow at the American College of Healthcare Executives, American Academy of Nursing and National Board of Corporate Directors.
D. James Surmeier, Ph.D., Chair of the Department of Physiology and Director of the Morris K. Udall Center of Excellence for Parkinson’s Disease Research at Northwestern University.
Jennifer Sweet, M.D., Assistant Professor of Neurosurgery at Case Western Reserve University School of Medicine and Neurosurgeon at University Hospitals Case Medical Center
V. Reggie Edgerton, Ph.D., Distinguished Professor in the Departments of Neurobiology, and Integrative Biology and Physiology and Neurosurgery at the University of California, Los Angeles and Member of the Brain Research Institute.
Rick Celebrini, PT, Ph.D., Co-founder of Fortius Institute, Head of Sports Medicine and Science for the Vancouver Whitecaps FC & Consultant to Vancouver Canucks, Vancouver 2010 Winter Olympics & Paralympics Chief Therapist and Medical Manager.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology holding company focused on neurological wellness. HMT seeks to use unique and non-invasive platform technologies that amplify its ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
- Investor Relations: 778-588-7144 or email@example.com
- Corporate Contact: Phil Deschamps, 614-596-2597 or firstname.lastname@example.org
- Media Contact: Becky Kern, 914-772-2310 or email@example.com
Safe Harbor Statement
All statements in this news release, other than statements of historical facts, are forward-looking statements. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include risks detailed from time to time in the filings made by the Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements except as required by applicable law.